Abstract: The present invention relates to the treatment of acidosis related diseases. In this study, the inventors have investigated how human monocytes adapt, survive and differentiate into macrophages under lactic acidosis. Experiments were conducted under atmospheric oxygen and in the presence of glucose, to rule out an effect of oxygen or glucose deprivation. Prolonged exposure to LA affected monocyte/macrophage metabolism. Extracellular acidosis induced mitochondrial membrane depolarization and significantly decreased nutrient consumption, resulting in a dependence of the macrophages on a transient phase of autophagy for survival. In fasting conditions, hepatocytes produce the ketone bodies acetoacetate (AcAc) and ?-hydroxybutyrate (?-OHB) that constitute alternative fuel for extrahepatic cells.

Abstract: A method for manufacturing a mechanoreception fabric for incorporation into a garment or item of apparel sets a liquid substrate to a fabric weave to produce a plurality of protuberances in graticulate array and spaced apart across a surface of the fabric. The plurality of protuberances includes pyramidal nodes, each independent and separate from other nodes, not less than 1 mm apart at the base and not more than 5 mm apart at each apex and 1.5 mm in height. Because the nodes are separated and not in contact with each other, the fabric produced is still stretchable and wearable when incorporated into an item of apparel despite the nodes having a hardness of between Shore A 60 and 80.

Abstract: A bactericidal and virucidal pharmaceutical composition for use on epithelial tissues such as pulmonary, nasal and oral tissues, which comprises a non-steroidal anti-inflammatory drug (NSAID) in a concentration between 5 and 500 mM and a salt, being the NSAID preferably solubilized in a hypertonic saline solution applicable in therapies for viral infections of the Herpes simplex type. The composition can be used in therapies for herpes simplex viral infections, be used as a bactericidal mouthwash, or be vehiculated to the lung by using a nebuliser, for cystic fibrosis.

Abstract: There is disclosed a nano-complex composition for topical drug delivery, comprising a diclofenac alkali metal salt, a cationic surfactant, glycol, or glycol ether or glycol ether ester, C2 to C3 alcohol, and water. The composition can further comprise hyaluronic acid. There is also provided a method of manufacture of nano-complex compositions for topical drug delivery. The compositions of the disclosure are useful in the treatment of joint pain, osteoarthritis, muscle pain, back pain and/or inflammation.

Abstract: A composition for generating nitric oxide includes a material containing a transition metal, and a compound. The composition for generating nitric oxide of the present invention may increase the level of nitric oxide to inhibit anticancer drug resistance and improve effects of anticancer chemotherapy.

Abstract: A topical aqueous antibiofilm, antimicrobial, and antiviral composition to disrupt biofilm to enhance the killing of microbial and viral particles in a way that prevents and reduces the severity of conditions and infections that are due to such microbial pathogens and viral particles is provided. The composition comprises a fatty acid chosen from saturated and/or unsaturated medium chain fatty acids (MCFAs: C-8 to C-12), saturated and/or unsaturated long chain fatty acids (LCFAs: C-13 to C-26), and/or their derivatives, salts, sugars and esters. The composition also comprises a solubilizing agent, preferably a cyclodextrin, which additionally synergizes the antibiofilm effect, and may be formulated for nebulization/inhalation. The composition further comprises chelating and enhancing agents, and either a neutral, acid or alkaline pH. The composition comprises skin and mucosal permeation enhancers, which improve clinical efficacy.

Abstract: The present disclosure provides a combination therapy for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH), wherein the combination therapy comprises an unsaturated fatty acid with an oxygen incorporated in the ?-position and an ?-substituent and at least one additional active agent chosen from a glucagon-like peptide 1 receptor agonist, an acetyl-CoA carboxylase inhibitor, and a farnesoid X receptor agonist.

Abstract: The invention is directed to tetrahydrocurcuminoid-metal complexes. The complexes can be included in compositions that further include additional nutraceutical antimicrobials, antioxidants, and immune boosters. The tetrahydrocurcuminoid-metal complexes can be administered to animals to increase animal health, reduce stress, reduce oxidative stress, maintain health, improve health, improve immunity, improve vaccination efficacy, increase feed conversion rate, decrease pro-inflammatory cytokine levels, or any combination thereof in an animal. The tetrahydrocurcuminoid-metal complexes of the invention exhibit enhanced bioavailability relative to the individual, non-complexed components.

Abstract: The present application includes an enantiomerically pure compound of Formula (R)-I or a salt and/or solvate thereof Also included are compositions of the enantiomerically pure compound of Formula (R)-I as well as methods of using the compound of Formula (R)-I or composition thereof for treating, for example, disease, disorder or condition that benefits from psychotherapy. The present application also includes a composition comprising a non-racemic mixture a compound of Formula (R)-I, or a salt and/or solvate thereof, and (S)-I, or a salt and/or solvate thereof: wherein (R)-I, or a salt and/or solvate thereof, is present in the composition in a greater amount by enantiomeric equivalents, relative to (S)-I, or a salt and/or solvate thereof and uses thereof. Further included are process preparing a compound of Formula (R)-I or (S)-I.

Abstract: Melatonin Agonist, MA-1, is administered at effective doses.

Abstract: The invention relates in one aspect to compounds, pharmaceutical compositions thereof, and methods using the same for selectively activating either all or a single isoform of Akt. Isoform selective-targeting is necessary for avoiding pathologies driven by concomitantly activated Akt1, Akt2 and/or Akt3.

Abstract: of treating Gram-negative bacteria that also exhibit resistance to the anti-bacterial compound colistin (MIC?50 mg/mL) except for Burkholderia, Proteus, and Serratia that comprises contacting the bacteria with an aqueous pharmaceutical composition containing a rose bengal (RB) compound of Formula I, below, dissolved or dispersed therein at a concentration of about 0.01 to about 15 mg/mL and irradiating those contacted bacteria with light of the wavelength about 500 nm to about 600 nm for a time period of about 1 to about 10 minutes to provide a light dose of about 16 to about 160 J/cm2, treat and kill the irradiated bacteria wherein X, R1, R2 and M+ are defined within.

Abstract: The invention involves the use of formulations of allosteric modulators of primarily 5ht2/5ht1, opiate or SERT serotonin transporter, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7, dopamine, GLP, and other receptors/systems, in combination with phenethylamines, tryptamines, ibogaloids as well as vaccines, antibodies and other compounds; to treat opiate dependency (addiction). Wherein opiate means, any opiate compound/mixture/drug, including, but not limited to synthetic, semisynthetic, natural, such as but not limited to opium, morphine, heroin, codeine, oxycodone, fentanyl, methadone, or other.

Abstract: The invention involves the use of formulations of allosteric modulators of primarily 5ht2/tht1, CB1 and GLP-1 serotonin transporter, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7 and other receptors, in combination with vaccines/antibodies, and phenethylamines, tryptamines, ibogaloids and other compounds; to treat or reduce symptoms of ingestion of drugs such as cannabis or 5-ht2a agonists. The method of delivery/formulation selected from: Inhaler, nebulizer, intravenously, intramuscularly, injection, capsules, tablets, pills.

Abstract: The invention involves the use of formulations of allosteric modulators of primarily 5ht2/tht1, CB1 and GLP-1 serotonin transporter, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7 and other receptors, in combination with phenethylamines, tryptamines, ibogaloids and other compounds; to treat or reduce symptoms of ingestion of drugs such as Cannabis or 5ht2a agonists. The method of delivery/formulation selected from: Beverage (soda, water, tea, coffee, or other), Candy (gum, gummy, chocolate, hard candy, taffy, or other), Food, smoking, vaping, e-cigarette, vape-pen, bong, vaporizer, tab, geltab, blotter, sublingual strip.

Abstract: The invention involves the use of formulations of allosteric modulators of primarily 5ht2/tht1, CB1, serotonin transporter and opiate receptors/systems, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7, dopamine, and other receptors, used before, after or in combination with phenethylamines, tryptamines, ibogaloids and other compounds; to increase the effects of ingestion of drugs such as Cannabis or 5-ht2a agonists. The method of delivery/formulation selected from: Beverage (soda, water, tea, coffee, or other), Candy (gum, gummy, chocolate, hard candy, taffy, or other), Food, smoking, vaping, e-cigarette, vape-pen, bong, vaporizer.

Abstract: Presented herein are methods and compositions for treating congenital diarrheal disorders (CDD). Methods comprise administering to a patient in need thereof, an effective amount of a proanthocyanidin polymer composition from C. lechleri, preferably crofelemer. Administration of the proanthocyanidin polymer composition addresses the secretory diarrhea and symptoms associated therewith caused by the CDD and can improve nutritional status, electrolyte balance, hydration, growth and development of the patient.

Abstract: The present disclosure relates to compositions as well as methods of use and methods of treating, including zinc ascorbate, hesperidin, quercetin, arginine, and calcidiol.

Abstract: The present application provides a method for improvement in physical activity efficiency, a method for reducing fatigue, and a method for improving dynamic/kinetic visual acuity, comprising administering a composition comprising a kaempferol analog to a subject in need thereof.

Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain a therapeutically effective amount of topiramate that is from 50 mg/ml to 100 mg/ml and amounts of polyethylene glycol (“PEG”) 400 and glycerol sufficient to result in a greater than a prior art taught calculated maximum amount of the topiramate being in the solution phase of the formulation, at room temperature.

Abstract: The present disclosure provides a sprayable liquid composition comprising about 1% w/v to about 20% w/v spironolactone or canrenone, about 30% w/v to about 97% w/v aliphatic solvent, about 1% w/v to about 10% w/v water, one or more film forming excipients, wherein the film forming excipient has a solubility in water at a pH between 1 and 10, and a penetration enhancer, wherein the composition forms a washable and/or a peelable film when sprayed on a skin surface, and wherein the spironolactone does not crystallize when the composition is applied to the skin surface. The disclosure also provides a method of treating acne, male and female pattern hair loss, hirsutism, hidradenitis suppurativa, polycystic ovary syndrome (PCOS), or combinations thereof in a subject in need thereof, the method comprising topically applying the composition described herein as a spray to a skin surface of the subject.

Abstract: The invention relates to a combination, combination for use, method for treating, kit, dosage regime, delivery device, method of adjuvant treatment, short-duration psychedelic agent for use, or parenteral formulation for use in the treatment of a psychiatric disorder in a patient. In particular, the invention relates to the administration of a short-duration psychedelic agent in combination with a monoamine antidepressant, such as a selective serotonin reuptake inhibitor (SSRI).

Abstract: The present invention discloses compositions, means and kits thereof for treating neuronal clinical indications in a mammalian subject. The composition comprises, inter alia, a synergistic combination of an anti-inflammatory drug and a DICER activator. The present invention further discloses methods for treating neuronal diseases including Motor neuron diseases (MNDs), ALS, FTD (Frontotemporal Dementia), macular degeneration (AMD) autism, and neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.

Abstract: The invention relates to administration at particular dosages of a compound which is a substituted 2-oxo-1-pyrrolidinyl triazole of formula (I) or an isomer or a pharmaceutically acceptable salt thereof.

Abstract: Methods of treating a disease characterized by amyloid aggregates are provided herein.

Abstract: Oral dosage forms of metaxalone having improved bioavailability in the fed and fasted states, including dosage forms that employ a reduced dose based on such improved bioavailability.

Abstract: The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) a agonist with a sodium glucose cotransporter 2 (SGLT2) inhibitor, which is to be used for preventing and/or treating nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.

Abstract: Provided is a pharmaceutical composition for preventing or treating allergic skin diseases or pruritus cutaneous, and more particularly, a pharmaceutical composition for preventing or treating allergic skin diseases or pruritus cutaneous including ABT-751 or TN-16 as an effective component, a cosmetic composition for preventing or improving allergic skin diseases or pruritus cutaneous including ABT-751 or TN-16 as an effective component, and a cosmetic composition for skin moisturizing including ABT-751 or TN-16 as an effective component are provided. The composition for preventing, improving, or treating atopic dermatitis according to the present invention was confirmed to effectively increase filaggrin expression in skin cells and improve a skin barrier function, thereby showing an effect of effectively improving or treating symptoms of pruritus cutaneous or allergic skin diseases including atopic dermatitis, and thus, showing an excellent skin moisturizing effect.

Abstract: A high potency, brain-permeable compound that inhibits Acyl-CoA:Cholesterol Acyltransferase 1 (ACAT1) activity is provided as are pharmaceutical compositions and methods for treating a disease, disorder, or condition mediated by ACAT1.

Abstract: This invention provides methods for the treatment of anemia in patients with chronic kidney disease (CKD) using vadadustat (Compound 1). Methods described herein provide alternative dosing regimens for patients having anemia. In addition, methods herein are suitable for patients converting from a previous anemia treatment including erythropoietin stimulating agent (ESA), patients who are on dialysis (e.g., peritoneal dialysis or hemodialysis), or CKD patients having certain hemoglobin (Hb) levels.

Abstract: Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

Abstract: Novel therapeutic uses of compounds for enhancing mitochondrial function and treating a mitochondrial disease are discovered by artificial intelligence (AI)-based in silico approaches. Methods of enhancing mitochondrial function and/or treating mitochondrial disease include administering an active compound to a subject in need. The active compound may be one or more compounds selected from the group consisting of preladenant, cinepazide, mitiglinide, deforolimus, mycophenolate-mofetil, megestrol, lercanidipine, fusidic acid, nimodipine, nicardipine, nitrendipine, benidipine, methazolamide, diethylcarbamazine, and pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to an anticancer agent capable of overcoming EGFR-TKI resistance in KRAS mutant cancer. GW8510 according to the present invention is an effective inhibitor against oncogenic mutation, especially, KRAS mutation, which is associated to resistance of the anticancer agent EGFR inhibitor and remarkably inhibits expression of both the wild-type and various mutants of KRAS, whereby the drug itself exhibits an anticancer effect, surmounts anticancer agent resistance, and noticeably promotes the death of anticancer agent-resistant cancer cells when used in combination with an anticancer agent. Thus, the inhibitor finds advantages applications in treating cancers, especially anticancer agent resistant cancers.

Abstract: The invention provides a compound of Formula (I) or a tautomer, isomer, prodrug, metal complex, or pharmaceutically acceptable salt thereof for use in the treatment of a metabolic disorder or for inducing weight loss: wherein R1 is: H; a straight or branched alkyl; a straight or branched alkyl substituted with at least one moiety selected from the group comprising: halogen, hydroxy, alkoxy, NH2, mono- or disubstituted amino, thiol, and phosphine; aryl; aralkyl; hydroxy; alkoxy; aryloxy; arylalkoxy; NH2; mono- or disubstituted amino; or halogen; X is: CH or N; L is absent or present, and when present is: an optionally substituted straight or branched C1-C10 alkyl, optionally containing one or more rings, and/or optionally containing one or more double bonds; and Ar is: an optionally substituted 5-membered unsaturated heterocyclic ring.

Abstract: Provided herein are methods of mitigating or reversing an aging-induced insulin resistance and/or elevation of fatty acids comprising a composition comprising a PPAR? agonist, or a pharmaceutically acceptable salt or prodrug thereof. Provided herein are methods of increasing lifespan comprising a composition comprising a PPAR? agonist, or a pharmaceutically acceptable salt or prodrug thereof, and uses thereof in animal health.

Abstract: The present invention relates generally to the treatment of a cancer that expresses a RAS mutation with a selective CDK9 inhibitor.

Abstract: The present disclosure relates to a ropivacaine suspension injection, and a preparation method therefor. Specifically, the ropivacaine suspension injection of the present disclosure comprises ropivacaine and a pharmaceutically acceptable excipient, wherein the median particle size D50 of the suspension injection is within the range of 1 ?m to 40 ?m. The ropivacaine suspension injection of the present disclosure can continuously release a drug in vivo, and has an analgesic effect of no less than 12 h, preferably, an analgesic effect of no less than 24 h, and more preferably, an analgesic effect of no less than 72 h.

Abstract: Some embodiments disclosed herein include a method for decreasing an expression level of a gene. The methods can include identifying a human subject having an increased expression level of hsp90; and administering to the human subject an effective amount of a nitroxide antioxidant, whereby expression level of the gene is decreased.

Abstract: The present invention relates to a method of improving the efficacy of treatment of line 2+ metastatic castration-resistant prostate cancer (mCRPC) with biallelic DNA-repair anomalies in a male human, wherein said biallelic DNA-repair anomalies are selected from: i) BRCA (BRCA1, BRCA2, or a combination thereof), ii) non-BRCA (ATM, FANCA, PALB2, CHEK2, BRIP1, HDAC2, or any combination thereof): or iii) any combination thereof; wherein the male human has received prior taxane-based chemotherapy and androgen receptor (AR)-targeted therapy; said method of improving the efficacy of treatment comprising administering to said male human a once-daily oral dosing of 300 mg niraparib.

Abstract: Methods of treating a BAF complex-related disorder, an SS18-SSX fusion protein-related disorder, a BRD9-related disorder, or cancer in a subject in need thereof are disclosed. The methods include the step of administering to the subject a regimen of an effective amount of compound S-D1 Compound S-DI, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to the use of an EZH2 inhibitor in the preparation of a drug for treating T-cell lymphoma. Specifically, the present invention relates to the use of a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating T-cell lymphoma.

Abstract: The present disclosure relates to ABCA1 inducer compounds for use in treating kidney disorders, and in particular, chronic kidney diseases, glomerular discases or proteinuric kidney diseases such as Alport syndrome, focal segmental glomerulosclerosis, and diabetic kidney discasc.

Abstract: Disclosed are pharmaceutical combinations and methods of treating a clinical condition, e.g., AML, by administering to a subject a pharmaceutical combination comprising a DHODH inhibitor and an anti-CD47-SIRP? therapeutic agent, such as an anti-CD47 antibody. The pharmaceutical combination can further comprise one or more additional therapeutic agents. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: A method of treating or preventing infection by an intracellular pathogen in a subject is described. The method includes administering to the subject a therapeutically effective amount of a composition including KH-1, KH-2, or a derivative and/or a pharmaceutically acceptable salt thereof. A method of treating or preventing bacterial inflammation in a subject is also described. New KH-1 and KH-2 derivatives are also described.

Abstract: A preparation comprising the YEL002 compound as an active ingredient for the prevention or treatment of one or more diseases, and methods of using such preparations. The preparations may be a sublingual pill, an injection, dissolved in liquid, dissolved in oil, or any other preparation. The conditions or diseases indicated may be psychological or psychiatric problems including anxiety/depression, aggression, alcoholism, drug and other addiction, insomnia, Alzheimer's and other dementia diseases, autism, schizophrenia, ADHD, PTSD, movement disorders and such.

Abstract: Provided are compositions and methods for administering paltusotine, or a pharmaceutically acceptable salt thereof, to a patient having hepatic impairment.

Abstract: A a drug delivery system having an inner core-shell like structure containing a poorly soluble camptothecin compound and a water-soluble camptothecin compound, and an outer amphiphilic polymer shell surrounding the inner core-shell like structure, a manufacturing method therefor, and uses of the drug delivery system in treating cancer are disclosed. The core-shell structured particles form very stable particles and show a mono-distribution of particles before and after freeze-drying. The particles show excellent results compared with existing particles which do not contain the inner core-shell like structure, in animal efficacy tests and pharmacokinetic tests.

Abstract: Chemical injuries to the eye can cause permanent vision impairment or blindness, as well as chronic pain and dry eye syndrome. Disclosed herein is a method of treating an ocular chemical burn by administering an effective amount of pergolide to an eye of a subject, such as via a topical formulation. Further disclosed are compositions and kits used for that treatment, such as pergolide solutions, and pergolide eye drop formulations.

Abstract: Provided herein is a 6?-naltrexol formulation at dosages sufficient for the treatment of a condition involving upregulated basal signaling of the ?-opioid receptor (MOR) system.